Navigation Links
Cautious Optimism for New Alzheimer's Medications, Reports the Harvard Mental Health Letter

BOSTON, Oct. 9 /PRNewswire-USNewswire/ --- Alzheimer's disease takes a long time to develop, which suggests that it may be possible to design drugs that work early in the disease process, to delay the start of symptoms. Over the past decade, researchers have been testing a number of such "disease-modifying" drugs that target the earliest biological changes in Alzheimer's, reports the October 2007 issue of the Harvard Mental Health Letter.

None of the disease-modifying drugs now in development will cure Alzheimer's. But a number of them are currently in phase III clinical trials, the last stage before the FDA will consider approving the drugs for sale. Media interest has already begun to intensify. In June, for example, the AARP Bulletin trumpeted on its cover: "Finally, new drugs offer real hope for reversing the disease."

Two experts interviewed by the Mental Health Letter temper the optimism with caution.

The experts note that questions remain whether these drugs will be effective enough to block Alzheimer's or safe enough to be taken for a long time and with other medications.

A larger issue is whether the drugs aim at the right targets. The new disease-modifying drugs target early biological abnormalities, especially the sequence of events involved in the creation of amyloid plaques (a hallmark brain lesion in Alzheimer's). Dr. Michael Miller, editor in chief of the Harvard Mental Health Letter, notes that although most of the research effort so far has focused on this stage, researchers are still developing their understanding of how Alzheimer's develops. "Scientists are encouraged by their research into the details of the genetic and environmental causes of Alzheimer's," he says. "They look forward to identifying other interesting targets of treatment as the science evolves."

Also in this issue:

-- Depression and sleep apnea

-- The spiritual aspects of recovery

-- Alcohol abuse and dependence

-- Repeat autism screening

-- Chemistry of fear

-- What is Internet addiction?

The Harvard Mental Health Letter is available from Harvard Health Publications, the publishing division of Harvard Medical School, for $59 per year. Subscribe at or by calling 1-877-649-9457 (toll free).

Media: Contact Christine Junge at for a complimentary copy of the newsletter, or to receive our press releases directly.

SOURCE Harvard Mental Health Letter
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Be cautious while on the Trampoline
2. Parents, More Cautious On Food Allergies
3. Precautious Measure Help Tolerate Nausea In Patients
4. Codeine-based painkillers to be used cautiously
5. Testing genes for disease does not cause harm to children of people with Alzheimers
6. Age-Dependent Alterations Not Specific For Alzheimers Disease
7. Killing two birds (cholesterol and Alzheimers disease) with the same stone
8. Exposure To High Aluminum Levels In Tap Water Lead To Rare Form Of Alzheimers
9. Sugar variant may make a world of difference to Alzheimers disease
10. Cancer Causing Protein May Heal Alzheimers
11. GAB2-A New Alzheimers Gene Identified
Post Your Comments:
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: